Ignite Creation Date:
2024-05-05 @ 10:26 PM
Last Modification Date:
2024-10-26 @ 10:18 AM
Study NCT ID:
NCT01105507
Status:
COMPLETED
Last Update Posted:
2017-03-21
First Post:
2010-03-25
Brief Title:
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes CAPS in Canada
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Cryopyrin Associated Periodic Syndrome |
Keywords:
| Name | View |
|---|---|
| Canakinumab | View |
| Cryopyrin-associated periodic syndromes | View |
| Familial Cold Autoinflammatory Syndrome FCAS | View |
| Familial Cold Urticaria FCU | View |
| Muckle-Wells Syndrome MWS | View |
| Neonatal-Onset Multisystem Inflammatory Disease NOMID | View |
| Chronic Infantile Neurological | View |
| Cutaneous | View |
| Articular Syndrome CINCA | View |
| Treatment of patients diagnosed with CAPS Cryopyrin associated periodic syndrome | View |